Latest Close
$2.38
Stock Hub
ACTU
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$7.95 (-76.96%)
Market Cap
$56,943,532.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$1.58 to $11.99
Target Mean Price
$9.98
Beta
Not available
Trailing P/E
Not available
Forward P/E
-2.80
Price / Book
14.88
Company Overview
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.